User profiles for Keith Sai Kit Leung
 | Keith Sai Kit LeungAcademic Foundation Doctor, Hull University Teaching Hospitals NHS Trust Verified email at nhs.net Cited by 834 |
Worldwide survey of COVID-19–associated arrhythmias
Background: Coronavirus disease 2019 (COVID-19) has led to over 1 million deaths worldwide
and has been associated with cardiac complications including cardiac arrhythmias. The …
and has been associated with cardiac complications including cardiac arrhythmias. The …
[HTML][HTML] Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis
Heart failure (HF) is a major epidemic with rising morbidity and mortality rates that encumber
global healthcare systems. While some studies have demonstrated the value of CRP in …
global healthcare systems. While some studies have demonstrated the value of CRP in …
[HTML][HTML] Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta …
Objectives Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1
receptor family. It is raised in various cardiovascular diseases, but its value in predicting …
receptor family. It is raised in various cardiovascular diseases, but its value in predicting …
Tpeak‐Tend, Tpeak‐Tend/QT ratio and Tpeak‐Tend dispersion for risk stratification in Brugada Syndrome: A systematic review and meta‐analysis
Background Brugada syndrome is an ion channelopathy that predisposes affected subjects
to ventricular tachycardia/fibrillation ( VT / VF ), potentially leading to sudden cardiac death (…
to ventricular tachycardia/fibrillation ( VT / VF ), potentially leading to sudden cardiac death (…
[HTML][HTML] Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched …
Introduction: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and dipeptidyl
peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 diabetes …
peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 diabetes …
[HTML][HTML] Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong
Recent studies have reported numerous predictors for adverse outcomes in COVID-19
disease. However, there have been few simple clinical risk scores available for prompt risk …
disease. However, there have been few simple clinical risk scores available for prompt risk …
Multi‐modality machine learning approach for risk stratification in heart failure with left ventricular ejection fraction≤ 45%
…, CH Ko, RWC Lai, T Liu, Y Liu, KSK Leung… - ESC heart …, 2020 - Wiley Online Library
Aims Heart failure (HF) involves complex remodelling leading to electrical and mechanical
dysfunction. We hypothesized that machine learning approaches incorporating data obtained …
dysfunction. We hypothesized that machine learning approaches incorporating data obtained …
[HTML][HTML] Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in …
Objective To compare the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2Is)
and dipeptidyl peptidase-4 inhibitors (DPP4Is) on adverse outcomes in diabetic patients in …
and dipeptidyl peptidase-4 inhibitors (DPP4Is) on adverse outcomes in diabetic patients in …
Territory-wide cohort study of Brugada syndrome in Hong Kong: predictors of long-term outcomes using random survival forests and non-negative matrix factorisation
Objectives Brugada syndrome (BrS) is an ion channelopathy that predisposes affected
patients to spontaneous ventricular tachycardia/fibrillation (VT/VF) and sudden cardiac death. …
patients to spontaneous ventricular tachycardia/fibrillation (VT/VF) and sudden cardiac death. …
Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users
Aims This study aimed to compare the rates of major cardiovascular adverse events in
sodium‐glucose cotransporter‐2 inhibitors (SGLT2I) and dipeptidyl peptidase‐4 inhibitors (DPP4I…
sodium‐glucose cotransporter‐2 inhibitors (SGLT2I) and dipeptidyl peptidase‐4 inhibitors (DPP4I…
